Transformative Role of SAMBA II in Winchester College’s COVID-19 Response

4 March 2024

Many congratulations to Dr John Cullerne, Undermaster at Winchester College, whose pioneering work on COVID-19 was recognised recently with an invitation to Buckingham Palace.

At the outset of the pandemic, and presented with the daunting challenge of how to accurately screen the College’s pupils before they returned to school, Dr Cullerne surveyed the different types of testing available, and noted that – with one exception –  systems required the presence of 1000 viruses within a single millilitre sample. The exception was Diagnostics for the Real World’s SAMBA II device – our fully automated ‘sample in, result out’ diagnostic machine for rapid point-of-care detection of infectious diseases.

With its capacity, at the time, to test at 250 per millilitre – a sensitivity four times that of conventional systems – Dr Cullerne recognised that DRW’s solution enabled the College to pool test and screen four pupils at a time, instead of one. This pool testing was unique, and made the screening of the entire pupil body possible in a way which was completely new. SAMBA II is currently deployed in over 100 UK hospital sites as one of the NHS’s primary point-of-care, non-lab-based COVID-19 testing solutions. SAMBA’s limit of detection is now improved to 150 copies/ml, demonstrating even greater performance.

Read more about how Dr Cullerne’s work, and how his ambitious and innovative solutions transformed Winchester College’s response to the COVID crisis here.

Other Articles

Browse other related news and activities

NHS hospitals adopt the next-generation SAMBA to improve patient care

Leading NHS hospitals have adopted the SAMBA III rapid molecular diagnostics platform to transform the way patients with suspected respiratory infections are assessed and managed. “Using SAMBA III will give us greater flexibility meaning that our patients are cared for in the...

29 September 2025

DRW receives CTDA approval for SAMBA III respiratory molecular tests

Diagnostics for the Real World (DRW) is pleased to announce that its SAMBA III SARS-CoV-2 Test and SAMBA III SCoV-2/Flu/RSV Test have received approval under the UK Coronavirus Test Device Approvals (CTDA) process. Following a successful desktop review by the UK’s Medicines and Healthcare...

8 August 2025

The launch of SAMBA III: a new generation of rapid molecular diagnostics

Diagnostics for the Real World (DRW), a pioneer in rapid molecular diagnostics, today announces the launch of the SAMBA III Instrument System – its most advanced point-of-care molecular platform to date. Building on more than two decades of innovation, SAMBA III has...

20 April 2025